School of Medicine

Showing 1-6 of 6 Results

  • Crystal Mackall

    Crystal Mackall

    Ernest and Amelia Gallo Family Professor and Professor of Pediatrics and of Medicine

    Current Research and Scholarly InterestsRecent clinical studies, by us and others, have demonstrated that genetically engineered T cells can eradicate cancers resistant to all other therapies. We are identifying new targets for these therapeutics, exploring pathways of resistance to current cell therapies and creating next generation platforms to overcome therapeutic resistance. We have discovered novel insights into the biology of human T cell exhaustion and developed approaches to prevent and reverse this phenomenon.

  • Everett Meyer

    Everett Meyer

    Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy), of Pediatrics (Stem Cell Transplantation) and, by courtesy, of Surgery (Abdominal Transplantation)

    Current Research and Scholarly InterestsResearch focus in T cell immunotherapy and T cell immune monitoring using high-throughput sequencing and genomic approaches, with an emphasis on hematopoietic stem cell transplantation, the treatment of graft-versus-host disease and immune tolerance induction.

  • Lekha Mikkilineni

    Lekha Mikkilineni

    Assistant Professor of Medicine (Blood and Marrow Transplantation & Cellular Therapy)

    BioDr. Lekha Mikkilineni is a board-certified medical oncologist. She is also an Assistant Professor in the Department of Medicine, Division of Blood & Marrow Transplant and Cellular Therapy.

    Dr. Mikkilineni has extensive experience treating blood and bone marrow cancers. She currently provides care through the Bone Marrow Transplant & Cellular Therapy Program at Stanford Health Care. Her clinical focus is multiple myeloma, plasma-cell leukemia, Extramedullary myeloma, high-risk myeloma, CAR T cell therapy, bispecific therapy, amyloidosis, POEMS syndrome, and Waldenstrom’s macroglobunemia.

    Dr. Mikkilineni’s research centers on exploring novel CAR T-cell therapies to treat multiple myeloma and to define mechanisms of resistance to immunotherapy. She is particularly focused on understanding how to improve therapies for multiple myeloma patients who have extramedullary disease or high-risk features. Prior to coming to Stanford, she ran phase 1 CAR T-cell trials for multiple myeloma targeting BCMA and SLAMF7 at the National Cancer Institute.

    Dr. Mikkilineni received the Conquer Cancer Foundation Young Investigator Award from the American Society of Clinical Oncology for her research focusing on SLAMF7 as a potential target for multiple myeloma. She has received honors and awards for her work at the NCI. She has completed fellowships in hematology/oncology and immunotherapy at the National Heart, Lung, and Blood Institute/National Cancer Institute. She finished her residency in internal medicine at Thomas Jefferson University Hospital. She holds a Master of Science in medical sciences from Boston University and a medical degree from Tulane University.

    Dr. Mikkilineni has authored book chapters and published research in numerous high-impact academic journals. She has presented her findings through oral and poster presentations at national and international conferences.

  • David Miklos

    David Miklos

    Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)

    Current Research and Scholarly InterestsDr. Miklos is the Chief of BMT & Cell Therapy Program. He leads clinical trials treating patients with lymphoma. His correlative research studies: 1) tumor antigen quantification, 2) single cell functional product characterization, 3) CAR-FACS immune phenotyping of blood and tumor, and identifying mechanisms for CAR-T treatment Failure including antigen loss, CAR-T exhaustion, and CAR suppression.

  • Lori Muffly

    Lori Muffly

    Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)

    Current Research and Scholarly InterestsDr. Muffly's interests include health services research and clinical trials with a focus on acute leukemia and blood and marrow transplantation.